Anti-VEGF Innovations in Retinal Disease
Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.
A recent Ophthalmology Times Case-Based Roundtable discussion focused on the structural differences among newer second-generation anti-VEGF agents and their implications for clinical efficacy and treatment durability.
The discussion highlighted real-world experiences and evidence regarding extended treatment intervals and sustained disease control with these newer therapies.
Case Study
Stewart, MD, described an 83-year-old woman with diabetic macular edema (DME) who had undergone temporal grid laser photocoagulation for macular edema and received bevacizumab (Avastin; Genentech, Inc) intravitreal injections every 4 to 6 weeks.
No direct quotes available in the given text.
Author's summary: Anti-VEGF agents improve retinal disease treatment.
More News
- Animal Crossing: New Horizons Gets a Free Update and Switch 2 Edition
- Disney Ended Doctor Who Partnership for These 3 Reasons
- Feds Say Kat Abughazaleh “Impeded” ICE Agents. That Would Put Her on the Right Side of History.
- Eala falls to Mboko to exit Hong Kong Open
- Equinix Reports Higher Earnings, Revenues and Capacity
- Equinix Grows Revenue, Buys Land, With 3 GW Of Capacity Now Under Development
- A Political Turning Point: Lessons from Sameer Suleman’s Election as Speaker of Malawi’s Parliament Malawi 24 | Latest News from Malawi
- CNN announces election night coverage plans, including All Access-only ‘livecast’
- Best early Black Friday deals 2025: 40+ sales out early
- St. Louis’ Gray Design Group adds senior project manager – REJournals